Lung Cancer—Non-Small Cell Local-Regional / Small Cell
LUNG CANCER—NON-SMALL CELL LOCAL-REGIONAL/SMALL CELL/OTHER THORACIC CANCERS 8500 Oral Abstract Session IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Heather A. Wakelee, Nasser K. Altorki, Caicun Zhou, Tibor Cso}szi, Ihor O. Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, Barbara J. Gitlitz, Elizabeth Bennett, Fan Wu, Jing Yi, Yu Deng, Mark McCleland, Enriqueta Felip; Stanford University Medical Center, Stanford, CA; New York- Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Tongji University Affiliated Shanghai Pul- monary Hospital, Shanghai, China; Ja�sz-Nagykun Szolnok Megyei Hete�nyi Ge�za Ko�rha�z-Rende- lointe�zet, Szolnok, Hungary; Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine; MI Zaporizhzhia Regional Clinical Oncological Dispensary, Zaporizhzhya, Ukraine; Leningrad Regional Clinical Hospital, Saint-Petersburg, Russian Federation; Pavlov State Medical University, Saint-Petersburg, Russian Federation; Medical Oncology Department, Vall d�Hebron University Hospital/Vall d�Hebron Institute of Oncology (VHIO), Barcelona, Spain; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital and Department of Medicine, National Yang-Ming University, Taipei, Taiwan; Unit of Pneumology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan; Genentech, Inc, South San Francisco, CA; Roche China, Shanghai, China; Genentech, Inc., South San Francisco, CA; Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain Background: Adjuvant platinum-based chemotherapy (chemo) provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC.
[Show full text]